RUBRA MEDICAMENTS LTD. - 531099 - Certificate Under Regulation 40 (10) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2019
Certificate Under Regulation 40 (10) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2019 Rubra Medicaments Ltd - 531099 - Shareholding for the Period Ended March 31, 2019
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here Rubra Medicaments Ltd - 531099 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Director RUBRA MEDICAMENTS LTD. - 531099 - Outcome of Board Meeting
Adoption of Codes of Fair Disclosure and Conduct as per SEBI (Prohibition of Insider Trading) Regulations, 2015 RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Adoption Of Code Of Fair Disclosures And Conduct
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/03/2019 ,inter alia, to consider and approve Adoption of code of fair disclosures and conduct RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Resignation of Director
Resignation of Independent Director RUBRA MEDICAMENTS LTD. - 531099 - Unaudited Financial Result For The Quarter Ended December 31, 2018
Unaudited financial result for the quarter ended December 31, 2018 Rubra Medicaments Ltd - 531099 - Board Meeting Intimation for Adoption Of Unaudited Financial Results For The Quarter Ended December 31, 2018 Along With Limited Review Report Thereon
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2019 ,inter alia, to consider and approve Adoption of Unaudited Financial Results for the Quarter ended December 31, 2018 along with Limited Review Report thereon Rubra Medicaments Ltd - 531099 - Shareholding for the Period Ended December 31, 2018
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here Rubra Medicaments Ltd - 531099 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Director